Background
Large randomized clinical trials of investigational agents in people with HIV (PWH) routinely exclude participants with adherence challenges. ACTG 5359, a phase III, prospective, randomized, open-label trial comparing long acting cabotegravir + rilpivirine (LAI) vs. oral standard of care (SOC) ART in PWH with a history of suboptimal adherence (persistent HIV-1 RNA >200 c/mL or loss to follow-up), successfully enrolled 437 participants in the US when an independent Data and Safety Monitoring Board recommended to stop randomization and offer LAI to all eligible participants at an interim review. Here we present transition status from induction phase to randomization with successive refinement of randomization eligibility.
Methods
Enrolled participants received conditional cash incentives for viral suppression along with a menu of adherence support strategies on SOC for up to 24 weeks prior to randomization (Step 1). Participants who achieved HIV-1 RNA ≤200 c/mL in Step 1 were eligible for randomization to monthly LAI vs. continuation of SOC ART for 52 weeks (Step 2). After study initiation (March 2019), the HIV-1 RNA threshold for Step 2 was increased from <50 c/mL to <200c/mL, and the minimum duration of Step 1 was progressively shortened from 20 weeks to 12 weeks (Dec 2021) and then to 4 weeks (Jan 2023).
Results
As of 3 Jan 2024, 878 participants screened and 437 eligible were enrolled. The most common screen failure reasons include HIV-1 RNA ≤200 c/mL (106, 25%), ineligible genotype/exclusionary mutations (93, 22%), and failure to return to clinic (48, 11%). Among those enrolled: median age 40 years, 70% male, 64% Black/African American, 17% Hispanic, 5% transgender, median CD4+ cells 270/mm3, and median HIV-1 RNA 3.55 log10 c/mL. Twenty percent had less than a high school education, 44% reported income of <$10k/year, and 10% were unstably housed/homeless. One-quarter screened positive for moderate/severe depression, 27% for moderate/severe anxiety, 32% for hazardous drinking, and 45% for drug use related problems. Of the 411 eligible for transition at the interim analysis, 61%, 77%, and 89% transitioned successfully to Step 2 with progressively shorter duration of viral suppression in Step 1(Table).
Conclusions
A5359 successfully enrolled a population not generally included in studies of investigational ART strategies and demonstrated that in-stream shortening of the required duration of virologic suppression significantly increased enrollment for the randomized strategy comparison.